Harnessing Gamma Frequencies to Modulate Alzheimer Pathology: Ralph Kern, MD, MHSc

The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]:

Source: Neurology Read More

Previous PostInvestigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study
Next PostPhase 2 RESCUE Data Show RNS60 Reduces Stroke Infarct and Improves Outcomes

Harnessing Gamma Frequencies to Modulate Alzheimer Pathology: Ralph Kern, MD, MHSc

Previous PostInvestigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study

Next PostPhase 2 RESCUE Data Show RNS60 Reduces Stroke Infarct and Improves Outcomes

Related Posts

<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>

<![CDATA[TEMPO-4 Extension Analysis: Tavapadon Shows Levodopa-Sparing Potential in Parkinson Disease]]>

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

Categories